Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineArticle Published on 2022-09-132022-11-15 Journal: Viruses [Category] SARS, 변종, 진단, [키워드] B.1.1.529 BNT162b2 collected COVID-19 dose evade Immunity Improved Lineage Mutation neutralisation assay neutralise neutralising Neutralising Antibodies neutralising antibody titre omicron Pfizer-BioNTech Pfizer-BioNTech BNT162b2 raising reduced SARS-CoV-2 sera the receptor-binding domain the SARS-CoV-2 the spike protein Vaccine vaccine. variant virus VoC World Health Organization [DOI] 10.3390/v14092023 PMC 바로가기
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults뉴질랜드 성인에서 BNT162b2 COVID-19 백신의 면역원성Article Published on 2022-08-122022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age All participant All participants analysed anti-S IgG Antibody Response baseline Beta BMI BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine Cellular immune response cellular immune responses co-morbidities Cohort COVID-19 COVID-19 disease COVID-19 vaccine declined Delta diabete diabetes diabetics disease dose enrichment Ethnic groups female Gender General population IgG immune response immune responses immunoassay immunogenicity in vitro International Lower Māori median age Microparticle morbidities morbidity naïve neutralise neutralising antibody neutralising response neutralising responses neutralizing capacity New obesity of BNT162b2 Older Older adults omicron other variant other variants Pacific Islander Population prospective cohort study pulmonary disease Quantitative recipient representation response risk robust SARS-CoV-2 vaccine second dose second vaccination serious COVID-19 seroconverted serum sample serum samples strain the vaccine Vaccine vaccine. variant Viral viral neutralisation Wuhan [DOI] 10.1016/j.vaccine.2022.07.009 PMC 바로가기 [Article Type] Article
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies회복기 및 백신 혈청 및 단일 클론 항체에 의한 SARS-CoV-2 오미크론 하위 변이체 BA.1 및 BA.2의 제한된 중화Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 addition antibody BA.1 BA.2 BNT162b2 booster booster dose booster vaccination breakthrough infections Casirivimab Cell Complete convalescent convalescent sera Delta dominant dose education Efficacy elicited exhibited expressing Frankfurt Imdevimab Immunity in vitro study individual infection with SARS-CoV-2 Limited majority median monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mutation neutralisation neutralise neutralising neutralizing capacity omicron Omicron variants reduced Region SARS-CoV-2 sera serum Sotrovimab specific resistance Spike protein supported tested the SARS-CoV-2 the spike protein therapy TMPRSS2 university vaccination Vaccine Vaccines variants variants of SARS-CoV-2 waning immunity Waning Immunity. [DOI] 10.1016/j.ebiom.2022.104158 PMC 바로가기 [Article Type] Article
Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice고온 내성 SARS-CoV-2 백신은 마우스에서 델타 및 오미크론에 대한 중화 항체를 유도합니다Article Published on 2022-04-132022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] AlphaFold antibody average biomolecular modelling Combination community transmission COVID-19 COVID-19 infection COVID-19 infections D614G mutation Delta derivative domain Efficacy elicit epitope Epitopes help human clinical trial IMPROVE in silico inaccessible mice monomeric neutralisation neutralise omicron phase Prevent Receptor-binding domain Receptor-binding domain (RBD) reduction reduction in responses against risk SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Thermotolerant thermotolerant vaccine titre trimeric unmet need Vaccine vaccine equity vaccine matching variants variants of concern variants of concern (VOC). VoC [DOI] 10.3390/v14040800 PMC 바로가기 [Article Type] Article
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months6개월 후 백신 단독 또는 SARS-CoV-2 감염 + 백신(하이브리드 면역)에 의해 유도된 항체에 의한 오미크론(B.1.1.529) 변이체의 차선 중화Article Published on 2022-04-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Against Anti-RBD IgG antibody B.1.1.529 BBV152 Biotechnology ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine correlation Covaxin Covishield cross-sectional cross-sectional study demonstrated Department exhibited explain foundation four group four groups geometric mean geometric mean titre GMT group groups hybrid Hybrid immunity Immune escape Immunity inactivated India individual Infection limit Live virus Live-virus neutralisation Melinda Gate Melinda Gates moderate natural infection nCoV neutralisation neutralisation assay neutralisation test neutralisation titre Neutralisation titres neutralise neutralising ability omicron Omicron variant outcome Primary outcome quantification Rapid reduction reduction in SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2. serum Significant Spread subjects tested titre USA vaccinated individual vaccinated individuals vaccination Vaccine variant virus Virus neutralisation [DOI] 10.1016/j.ebiom.2022.103938 PMC 바로가기 [Article Type] Article
Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds표준화된 정량적 중화 분석을 사용하여 우려되는 SARS-CoV-2 변이체의 중화 계층은 질병 심각도와의 상관관계를 보여줍니다. 보호항체 역치를 해독하기 위해Article Published on 2022-03-072022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단, [키워드] (Alpha) (Beta) 20/136 Alpha anti-SARS-CoV-2 anti-SARS-CoV-2 immunoglobulin antibody Antibody titre Asymptomatic B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta Cohort concern convalescent sera correlates of protection (CoP) COVID-19 Critical care Delta did not produce disease disease severity First wave Gamma HCW HCWs healthcare worker Healthcare workers hierarchy Immunoglobulin individual International international standard international units IU/mL K417N Laboratory laboratory findings mild case mild cases National neutralisation neutralise P.1 Pseudotyped virus pursuit reduction in SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sera severe COVID-19 Standard Symptoms the WHO threshold titre titres to define unit utilised variants variants of concern variants of concern. variants of interest VoC VOCs WHO World Health Organisation [DOI] 10.3389/fimmu.2022.773982 PMC 바로가기 [Article Type] Article
Titres and neutralising capacity of SARS-CoV-2-specific antibodies in human milk: a systematic review모유 내 SARS-CoV-2 특이 항체의 역가 및 중화 능력: 체계적인 검토Article Published on 2022-03-012022-09-12 Journal: Archives of disease in childhood. Fetal and neonat [Category] MERS, SARS, 진단, [키워드] anti-SARS-CoV-2 antibody articles Asymptomatic asymptomatic infection CINAHL CNKI COVID-19 COVID-19 infection current database demonstrated disease Evidence Google Scholar Holder Human human milk IgA IgG IgM illness immunoglobulin A in vitro individual individuals with COVID-19 Infection lactating Mild milk neonatology neutralise neutralising Neutralising Antibodies neutralising antibody outcome performed Presence preserved provided SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 virus SARS-CoV-2-specific antibody selected severe disease severity Study design systematic review tested Virology. WHO with COVID-19 [DOI] 10.1136/archdischild-2021-322156 PMC 바로가기 [Article Type] Article
A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic ApplicationReview Published on 2022-02-232022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] alpha-1 antitrypsin alpha-1 antitrypsin deficiency anti-inflammatory activity antitrypsin application binding canonical Cell changes in circulation cleavage Complement C3 complex Coronavirus disease 2019 (COVID-19) Critical cytokine Cytokines disorder electrostatic hydrophobic immune response immunomodulatory increasingly innate immune interactions interleukin-6 mechanism methionine modulate molecular neutralise partner Potential protease Proteases Protein protein-protein interaction reactive residue review serine protease inhibitor therapeutic therapy [DOI] 10.3390/ijms23052441 PMC 바로가기 [Article Type] Review
Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021Medicine Published on 2022-01-202022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] activity analysed Analysis anti-nucleoprotein Breakthrough infection characterisation Characteristics Clinical course clinical feature Clinical features collected conducted coronavirus disease Course COVID-19 COVID-19 pandemic defined Diagnosis dose effective evaluated events feature Gamma genomic hospitalisation immunological individual Infection Infectious disease Isolation Italy Lazio less majority measure median Mild MOST mRNA BNT162b2 mRNA BNT162b2 vaccine NAb neutralise Neutralising Antibodies NPs NPSs occurred Patient pauci/asymptomatic Post-vaccine proportion Protein RBD receiving Region reported Result Rome SARS-CoV-2 SARS-CoV-2 variant serological serum serum sample significantly single dose spike statistically significant Substitution Surveillance Swab Symptom symptomatic case titre vaccination Vaccine vaccine breakthrough infections vaccine dose vaccinees variant variants Viral load Viral variants Virological [DOI] 10.3389/fmed.2021.815870 PMC 바로가기 [Article Type] Medicine
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형Research Article Published on 2021-12-022022-08-13 Journal: PLoS Pathogens [Category] Biochemistry, SARS, 변종, 진단, [키워드] (Beta accumulation African antibody Antibody titre antigenic antigenic drift antigenic profiles assessment Astra Zeneca Author B.1.351 B.1.617.1 B.1.617.2 bat bats Beta BNT162b2 BNT162b2 vaccines Booster vaccine booster vaccines ChAdOx1 changes in collected COVID-19 COVID19 death decrease decreases Delta delta variant dose effective Effectiveness Efficacy elicited evade expressed facilitate fold Fold changes glycoprotein groups hospitalisation Human human cell human cells humans Immunity India indicated individual Infection Lineage magnitude Mutation neutralisation neutralise Neutralising Antibodies neutralising antibody titres of BNT162b2 Pfizer Pfizer/BioNTech Prevent profile protective immune response pseudoviruses recipient recipients reduced reduction reduction in reductions reductions in required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sensitivity sera Severe infection shape significantly higher South South Africa spike glycoprotein spike glycoproteins Spike protein subsequent the spike protein titre vaccinated individuals vaccination Vaccine vaccine efficacy Vaccines variant variant B.1.617.2 variants variants of concern Viral viral variant Viral variants virus Virus spike VOCs while with infection with infections Wuhan Wuhan, China [DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article